) reached a 52-week high of $72.64 on Jul 5, 2013. The closing
price of $72.12 of the company reflects a robust year-to-date
return of 32.1%.
The specialty biopharmaceutical company has a market cap of $4.2
billion. Average volume of shares traded over the last three
months stood at approximately 1,021.3K.
The Growth Story
Shares of the company started escalating following the release of
its impressive first quarter results on May 7, after the close of
the financial markets. The increase can be attributed to strong
first quarter results and an upwardly revised guidance.
Jazz Pharma raised its 2013 adjusted earnings guidance to $6.10
to $6.30 per share, up from the earlier guidance of $5.70 to
$5.90. The company also revised its revenue guidance for 2013
upwards to $830-$860 million from the earlier range of $805-$835
Performance of the company's key growth drivers, Xyrem and
Erwinaze, were promising in the first quarter of 2013. While
Xyrem sales increased 60% to $117.5 million, Erwinaze generated
revenues of $41.8 million, up 27.1% year over year.
Both products are witnessing strong demand, which is expected
to boost revenues. Xyrem net sales in 2013 are expected in the
range of $540-$555 million as compared to $378.7 million in 2012.
In 2013 Erwinaze net sales are expected in the range of $150-$175
million compared with $72.1 million in the prior year.
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
SALIX PHARM-LTD (SLXP): Free Stock Analysis
SANTARUS INC (SNTS): Free Stock Analysis
VALEANT PHARMA (VRX): Free Stock Analysis
To read this article on Zacks.com click here.
On a price-to-sales basis Jazz Pharma is trading at 6.5x,
reflecting a huge premium of 103.1% compared with the peer group
average of 3.2x. On a price-to-book basis, the stock is also
trading at a premium to the peer group average. Given the
company's strong fundamentals, the premium valuation is
For 2013, the Zacks Consensus Estimate moved north 4.3% to $5.58
per share over the last 90 days. For 2014, the Zacks Consensus
Estimate moved up 10.5% to $7.28 per share over the same time
Jazz Pharma carries a Zacks Rank #1 (Strong Buy). Other Zacks
Rank #1 companies include